

• Οργάνωση:

Εταιρεία Ιατροβιολογικής  
Έρευνας του Καρκίνου

• Σε συνεργασία:

Τμήμα Ακτινοθεραπευτικής  
Ογκολογίας Γ.Ν.Α. «Αλεξάνδρα»  
Ογκολογική Κλινική, Π.Γ.Ν. Αλεξανδρούπολης

WEB EVENT

ΠΑΝΕΛΛΗΝΙΟ ΣΥΝΕΔΡΙΟ

## Σύγχρονα Θέματα ΟΓΚΟΛΟΓΙΑΣ



MARC CHAGALL. MONOTYPES EN NOIR ET EN COULEURS. 1961-1963

Θα χορηγηθούν  
22 Μόρια Συνεχιζόμενης  
Ιατρικής Εκπαίδευσης  
(CME-CPD)

17 - 19 ΜΑΡΤΙΟΥ 2022

Επιστημονικό ΠΡΟΓΡΑΜΜΑ

# ακτινοθεραπεία των καρκίνων κεφαλής & τραχήλου υπάρχουν εξελίξεις;


Ιωάννης Γεωργακόπουλος  
Ακτινοθεραπευτής Ογκολόγος

# epidemiology


- ✓ globally 2017:
  - 890000 new cases (5.3 % of all cancers)
  - 507000 deaths (5.3% of all cancer deaths)
- ✓ 1990 to 2017, incidence rates for larynx and nasopharyngeal cancers decreased, whereas they increased for other pharyngeal cancers and lip/oral cavity cancers

# epidemiology


Laryngeal cancers




Nasopharyngeal cancers



Oral cavity cancers



Other pharyngeal cancers



# risk factors

- ✓ tobacco
- ✓ alcohol
- ✓ chronic viral infection (HPV, EBV)
- ✓ betel nut chewing
- ✓ male gender
- ✓ genetic susceptibility
- ✓ occupational exposure
- ✓ malnutrition
- ✓ poor dental care
- ✓ mechanical irritation

# treatment modalities

surgery

radiotherapy

chemotherapy

new agents

**as single modality or in combination**

(generally recommended for the approximately 30 to 40% of patients who present with early-stage disease, stage I or II)

**combined modality treatment**

(generally recommended for the approximately 60% of patients with locally or regionally advanced disease at diagnosis)

**alone or in combination with RT, ChTRT**

# considerations in decision making

- ✓ pretreatment considerations
  - comorbidities
  - malnutrition
  - oral health
- ✓ morbidity of treatment
- ✓ what do patients want?

# major issues regarding (ChT)RT in locally advanced HNCa

- ✓ induction ChT
- ✓ induction ChT vs concurrent chemoradiotherapy
- ✓ adjuvant ChT
- ✓ cisplatin bolus vs weekly administration
- ✓ cisplatin vs carboplatin
- ✓ Cetuximab plus radiotherapy
- ✓ other EGFR inhibitors plus chemoradiation
- ✓ Cetuximab vs cisplatin for definitive chemoradiation
- ✓ immunotherapy plus chemoradiation

# guidelines

- ✓ major role of RT both in early & advanced stages
- ✓ plus ChT or other agents in multimodal setting  
for unresectable disease or organ preservation approaches



# outline

- ✓ technological advances in photon based RT
  - 2D/3DCRT vs IMRT
- ✓ expand indications of RT
  - reirradiation of recurrent disease
  - hadrontherapy
- ✓ deintensified RT in HPV related OPC

technological advances in photon based RT